Clinical Trials Search Tool

A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis

Disease/Condition: Atopic Dermatitis

Location: Gresham

Ages: 2-5 years of age

Enrollment Opens: 06-30-2021

Enrollment Closes: TBD


This is a phase 3, parallel group, double blind, vehicle-controlled study in which ARQ-151 cream
0.05% or vehicle is applied QD x 4 weeks to subjects aged 2-5 years with mild to moderate atopic

Study ID: ARQ-151-315

To Enroll: Contact Cyn3rgy Research at; 503-907-2179 ext. 4 or visit us on the web at

Posted by: Cyn3rgy Research |